Book a Meeting

Anti-CCL11 Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP370) (CAT#: AES-0622-ZP370) Datasheet

Target
CCL11
Description
Anti-CCL11 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CCL11 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
C-C Motif Chemokine Ligand 11
Background
Bertilimumab; cat-213; 375348-49-5; CAT-213; CAT213; iCo-008; CAT-212; CCL11; chemokine (C-C motif) ligand 11; SCYA11; small inducible cytokine subfamily A (Cys Cys); member 11 (eotaxin); eotaxin; eotaxin 1; MGC22554; eotaxin-1; C-C motif chemokine 11;
Antibody Clone
AES-0622-ZP370
Description
Anti-CCL11 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.